Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Return on Equity (2016 - 2025)

Historic Return on Equity for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 0.59%.

  • Viridian Therapeutics, Inc.\DE's Return on Equity fell 1800.0% to 0.59% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.59%, marking a year-over-year decrease of 1800.0%. This contributed to the annual value of 0.48% for FY2024, which is 800.0% up from last year.
  • Latest data reveals that Viridian Therapeutics, Inc.\DE reported Return on Equity of 0.59% as of Q3 2025, which was down 1800.0% from 0.61% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Return on Equity's 5-year high stood at 0.32% during Q4 2022, with a 5-year trough of 1.3% in Q2 2021.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's median Return on Equity value was 0.49% (recorded in 2022), while the average stood at 0.6%.
  • Its Return on Equity has fluctuated over the past 5 years, first soared by 11700bps in 2021, then crashed by -3300bps in 2023.
  • Quarter analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Return on Equity stood at 0.41% in 2021, then rose by 20bps to 0.32% in 2022, then crashed by -103bps to 0.66% in 2023, then soared by 40bps to 0.39% in 2024, then plummeted by -52bps to 0.59% in 2025.
  • Its Return on Equity was 0.59% in Q3 2025, compared to 0.61% in Q2 2025 and 0.48% in Q1 2025.